• Canagliflozin: Mitochondrial Remodeling in Renal Disease Res

  2026-07-23

  This thought-leadership article examines how Canagliflozin, a potent SGLT2 inhibitor, reshapes translational research into diabetes and kidney disease by targeting mitochondrial networks in the renal proximal tubule. We synthesize mechanistic findings, strategic guidance, and workflow optimization to empower researchers to move beyond glycemic endpoints and unlock new paradigms in metabolic disease modeling.

• CIP2A Drives PKM2 Tetramerization and OXPHOS in NSCLC Metabo

  2026-07-23

  The referenced study reveals that the oncoprotein CIP2A promotes oxidative phosphorylation in non-small cell lung cancer (NSCLC) by inducing PKM2 tetramer formation and mitochondrial localization, challenging the traditional Warburg effect paradigm. These findings provide new perspectives on metabolic vulnerabilities in NSCLC and inform the design of targeted anticancer strategies.

• Nicotinamide Adenine Dinucleotide (NAD+): Applied Workflows

  2026-07-22

  Nicotinamide Adenine Dinucleotide (NAD+) unlocks reproducible, high-fidelity metabolic and stress response assays, bridging bench precision and translational promise. This guide delivers actionable protocols, troubleshooting strategies, and novel insights that leverage APExBIO’s NAD+ for next-generation metabolic research.

• Protein A/G Magnetic Co-IP/IP Kit: Advanced Co-IP Workflows

  2026-07-22

  Unlock the true potential of recombinant Protein A/G magnetic beads for high-efficiency co-immunoprecipitation, antibody purification, and protein-protein interaction analysis. This guide translates bench research into actionable protocols, addresses common pitfalls, and highlights innovations validated in Babesia research and beyond.

• ATS-9R: Precision Gene Silencing in Adipocytes Made Practica

  2026-07-21

  ATS-9R (Adipocyte-targeting sequence-9-arginine) empowers researchers to achieve targeted, efficient, and low-toxicity gene delivery specifically in white adipose tissue. This platform unlocks advanced metabolic disease research through prohibitin-mediated endocytosis and robust gene knockdown, with streamlined workflows and minimal off-target effects.

• Lisinopril Dihydrate: ACE Inhibition Specificity and Assay I

  2026-07-21

  Explore the scientific foundation and assay-critical selectivity of Lisinopril dihydrate, a potent ACE inhibitor. This article uniquely addresses specificity pitfalls and practical assay design for hypertension and heart failure research.

• HDAC8-Driven AKT Activation in MEK1/2 Inhibitor-Resistant Ca

  2026-07-20

  This study uncovers how HDAC8 mediates resistance to MEK1/2 inhibition in cancer cells by upregulating PLCB1 and suppressing DESC1, thereby activating AKT. The findings point to PLCB1 and DESC1 as potential targets to overcome resistance mechanisms in targeted cancer therapies.

• 3-Hydroxybutyrate (BHBA): Optimizing Neuroprotection Protoco

  2026-07-20

  3-hydroxybutyrate (BHBA) offers cutting-edge versatility as both a metabolic signaling molecule and a class I HDAC inhibitor for advanced neuroprotection models. This article details actionable workflows, troubleshooting guidance, and translational insights to maximize BHBA’s impact in ferroptosis and stroke research.

• TECPR1 Drives Lysosomal Repair via Membrane Tubulation in En

  2026-07-19

  This study reveals that TECPR1 is essential for repairing damaged lysosomal membranes during glucose starvation, acting through membrane tubulation with KIF1A. The findings advance understanding of lysosome quality control under metabolic stress and have implications for metabolic and lysosome-related disorders.

• Praeruptorin A Attenuates Acute Ulcerative Colitis via STAT-

  2026-07-18

  This study establishes that Praeruptorin A, an angular pyranocoumarin compound from Peucedanum praeruptorum Dunn, alleviates DSS-induced ulcerative colitis in mice by targeting the STAT-1/-3 signaling pathway. The findings highlight a mechanistic link between STAT pathway inhibition, reduced inflammation, and restoration of intestinal barrier integrity, offering new avenues for anti-inflammatory agent development in ulcerative colitis.

• Antibacterial Use and Resistance Patterns in Psychiatric Hos

  2026-07-17

  This study provides a detailed analysis of antibacterial drug use and resistance trends in a psychiatric hospital during the 2022 epidemic. The findings highlight the importance of rational antibiotic stewardship and ongoing resistance monitoring in specialized healthcare settings, particularly during infectious disease outbreaks.

• Direct Mouse Genotyping Kit Plus: Streamlining Genomic Workf

  2026-07-17

  The Direct Mouse Genotyping Kit Plus accelerates mouse genotyping by combining rapid, purification-free DNA extraction with a high-fidelity PCR master mix containing dye reagents. This kit empowers researchers to efficiently validate gene knockouts, detect transgenes, and screen animal colonies, making it a best-in-class solution for high-throughput and translational mouse genetics.

• Red Blood Cell Lysis Buffer: Precision Tools for Osteogenic

  2026-07-16

  Translational studies in bone biology demand reliable blood sample preparation—especially for mechanistic exploration of osteogenic pathways such as RUNX2-AMPK. This article offers a strategic perspective on how ammonium chloride-based Red Blood Cell Lysis Buffer enables selective erythrocyte removal, preserves lymphocytes, and empowers cutting-edge research from nucleic acid extraction to flow cytometry. We bridge mechanistic literature with best-practice protocols, evaluate the competitive landscape, and chart a visionary outlook for hematological and osteoimmunological research.

• Cyclosporin A: Molecular Mechanisms and Assay Innovation

  2026-07-16

  Explore the molecular intricacies of Cyclosporin A, focusing on its dual roles in immunosuppression and mitochondrial research. This article uniquely bridges structural insights with practical assay guidance, advancing beyond existing protocols.

• α-Linolenic Acid: Elevating Translational Lipidomics and Imm

  2026-07-15

  This thought-leadership article explores the pivotal mechanistic and strategic roles of α-Linolenic Acid (ALA) in translational lipidomics and immunometabolic research. Framed for researchers seeking to bridge preclinical discovery with clinical impact, the piece integrates the latest evidence on omega-3 polyunsaturated fatty acids, cross-domain insights into immune modulation, and practical protocol parameters. By critically comparing ALA with recent breakthroughs in arachidonic acid–driven humoral immunity, it highlights opportunities and limitations in leveraging ALA for next-generation research. The article provides actionable guidance for optimizing experimental design and positions APExBIO’s α-Linolenic Acid as the reagent of choice for advancing the field.

17047 records 4/1137 page Previous Next 12345 下5页 Last page